Edwards Lifesciences Corp (EW) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has...
Edwards Lifesciences Corp's revenue increased 11.5% year over year, from $5.44B to $6.07B.
Net income decreased 74.3% over the same period, from $4.17B to $1.07B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 105% in total.
Total debt remained relatively stable at $598.3M.
The debt-to-equity ratio stands at 0.06, indicating a conservative leverage profile.
Operating cash flow grew 194.2% to $1.60B.
Edwards Lifesciences Corp maintains a healthy net profit margin of 17.7%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $4.47B+49.5% | $1.03B | $3.45B | $1.13B | $759.2M | $9.37B | $596.8M | $6.66B |
| Q1 FY2024 | $1.60B-64.3% | $351.9M | $1.21B | $387.5M | $-53.5M | $9.74B | $597.2M | $7.12B |
| Q2 FY2024 | $2.73B+71.0% | $718.2M | $2.15B | $720.2M | $318.0M | $10.10B | $597.3M | $7.44B |
| Q3 FY2024 | $4.05B+48.3% | $3.79B | $3.23B | $1.07B | $669.8M | $12.97B | $597.5M | $9.55B |
| Q1 FY2025 | $1.41B-65.2% | $358.0M | $1.11B | $394.8M | $280.4M | $13.02B | $597.8M | $10.13B |
| Q2 FY2025 | $2.94B+108.5% | $691.2M | $2.30B | $806.0M | $570.6M | $13.49B | $598.0M | $10.55B |
| Q3 FY2025 | $4.50B+52.7% | $982.3M | $3.51B | $1.11B | $1.14B | $13.27B | $598.2M | $10.21B |
| Q1 FY2026 | $1.65B-63.3% | $380.7M | $1.29B | $477.6M | $43.8M | $13.32B | $598.5M | $10.33B |
Balance Sheet Summary (Latest Period)
Total Assets
$13.70B
Total Liabilities
$3.36B
Total Equity
$10.34B
Cash & Equivalents
$4.23B
Total Debt
$598.3M
Current Assets
$6.74B
Current Liabilities
$1.81B
Retained Earnings
$14.24B